Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20.

Rituximab has never been investigated in MRD persistence/relapse. We describe a clinical picture of a woman with Ph-negative B-ALL CD20+, ineligible to allogeneic transplant, achieving MRD eradication using rituximab monotherapy after frontline chemotherapy and blinatumomab failure. This demonstrates rituximab's potential in MRD+ Ph-negative B-ALL CD20+, warranting further clinical investigation.